Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:GPCRNASDAQ:RGNXNASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$7.63-2.5%$8.03$5.08▼$10.67$1.04B1.161.33 million shs393,072 shsGPCRStructure Therapeutics$22.60-5.4%$20.98$13.22▼$62.74$1.32B-1.69926,560 shs128,752 shsRGNXREGENXBIO$8.18$7.39$5.04▼$16.85$411.06M1.11857,520 shs200,496 shsSYRESpyre Therapeutics$14.63-0.8%$15.16$10.91▼$40.49$883.65M2.78607,606 shs80,271 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals-3.69%-3.87%+5.53%+0.13%+55.78%GPCRStructure Therapeutics-2.97%-5.65%+50.25%-1.81%-33.62%RGNXREGENXBIO+2.63%+3.28%+38.88%+13.61%-48.03%SYRESpyre Therapeutics-1.21%+17.91%+20.70%-36.61%-60.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.6895 of 5 stars3.51.00.00.03.30.81.9GPCRStructure Therapeutics2.1709 of 5 stars3.51.00.00.03.21.70.6RGNXREGENXBIO3.9874 of 5 stars3.41.00.04.62.62.50.6SYRESpyre Therapeutics3.081 of 5 stars4.60.00.00.04.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5050.82% UpsideGPCRStructure Therapeutics 3.00Buy$78.00245.19% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63286.61% UpsideSYRESpyre Therapeutics 3.25Buy$53.40265.13% UpsideCurrent Analyst Ratings BreakdownLatest RGNX, GPCR, SYRE, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $75.005/5/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$65.005/2/2025GPCRStructure TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.004/22/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.004/8/2025SYRESpyre TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/8/2025SYRESpyre TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$45.003/20/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.003/18/2025RGNXREGENXBIOLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.003/18/2025SYRESpyre TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$27.003/17/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $34.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M4.43N/AN/A$2.63 per share2.90GPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/ARGNXREGENXBIO$83.33M4.92N/AN/A$7.09 per share1.15SYRESpyre Therapeutics$890K990.49N/AN/A($0.22) per share-66.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M$0.05N/A13.62N/A-10.23%-4.41%-3.07%N/AGPCRStructure Therapeutics-$89.62M-$0.87N/AN/AN/AN/A-16.37%-15.68%N/ARGNXREGENXBIO-$263.49M-$4.61N/AN/AN/A-283.19%-70.65%-41.68%5/14/2025 (Estimated)SYRESpyre Therapeutics-$338.79M-$3.77N/AN/AN/AN/A-210.01%-44.40%N/ALatest RGNX, GPCR, SYRE, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/A5/8/2025Q1 2025SYRESpyre Therapeutics-$0.76-$0.74+$0.02-$0.74N/AN/A3/13/2025Q4 2024RGNXREGENXBIO-$1.27-$1.01+$0.26-$1.01$23.70 million$21.21 million2/27/2025Q4 2024GPCRStructure Therapeutics-$0.23-$0.22+$0.01-$0.22N/AN/A2/27/2025Q4 2024SYRESpyre Therapeutics-$0.89-$0.81+$0.08-$0.81$2.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.175.605.11GPCRStructure TherapeuticsN/A27.6327.63RGNXREGENXBION/A3.053.05SYRESpyre TherapeuticsN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%GPCRStructure Therapeutics91.78%RGNXREGENXBIO88.08%SYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals4.30%GPCRStructure Therapeutics9.43%RGNXREGENXBIO12.79%SYRESpyre Therapeutics6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300136.65 million137.02 millionOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableRGNXREGENXBIO37050.12 million43.04 millionOptionableSYRESpyre Therapeutics10060.28 million48.24 millionOptionableRGNX, GPCR, SYRE, and AUPH HeadlinesRecent News About These CompaniesHow Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%May 13 at 11:00 AM | zacks.comJefferies Financial Group Inc. Has $28.33 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 13 at 7:54 AM | marketbeat.comFirst Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 12 at 3:18 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Up 12.6% After Strong EarningsMay 11 at 1:35 AM | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)May 10, 2025 | theglobeandmail.comDeerfield Management Company L.P. Series C Purchases Shares of 450,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 10, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Holdings Raised by Driehaus Capital Management LLCMay 10, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 9, 2025 | finanznachrichten.deDeep Track Capital LP Lowers Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 9, 2025 | marketbeat.comSpyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | prnewswire.comBraidwell LP Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 8, 2025 | marketbeat.comBlackstone Inc. Acquires 156,206 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 8, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 5.8% - Here's WhyMay 7, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from WedbushMay 7, 2025 | marketbeat.comWhy Spyre Therapeutics, Inc.’s (SYRE) Stock Is Down 5.11%May 7, 2025 | aaii.comSpyre Therapeutics' (SYRE) "Outperform" Rating Reiterated at WedbushMay 7, 2025 | americanbankingnews.comInvesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 6, 2025 | marketbeat.comSpyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001May 5, 2025 | prnewswire.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from AnalystsMay 5, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Acquires 77,323 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 5, 2025 | marketbeat.comBoxer Capital Management LLC Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)May 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGNX, GPCR, SYRE, and AUPH Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$7.63 -0.19 (-2.47%) As of 11:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Structure Therapeutics NASDAQ:GPCR$22.60 -1.30 (-5.42%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.REGENXBIO NASDAQ:RGNX$8.18 +0.00 (+0.05%) As of 11:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Spyre Therapeutics NASDAQ:SYRE$14.62 -0.13 (-0.85%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oklo Reaches Critical Mass, Atomic Upside Still Available U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal D-Wave Pushes Back on Short Seller Case With Strong Earnings NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
